Related Experiment Video

Updated: Aug 12, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

[Attempt to use cefpiramide (Tamicin) in patients with infectious destructive lung diseases]

S E Kuleshov, V S Zabrosaev, A V Ovsiankin

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |February 1, 1995
    PubMed

    Insights

    Cefpiramide demonstrated high clinical efficacy (88.2%) in treating lung infections. This antibiotic showed good tolerance, with adverse reactions in only 11.7% of patients.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Pulmonology

    Context:

    • Severe and complicated infectious destructive lung lesions pose significant treatment challenges.
    • Evaluating novel antibiotic therapies is crucial for managing resistant bacterial infections.

    Purpose:

    • To assess the clinical efficacy and tolerance of cefpiramide in patients with infectious destructive lung lesions.
    • To determine the in vitro susceptibility of various aerobic and anaerobic bacteria to cefpiramide.

    Summary:

    • Cefpiramide achieved an 88.2% clinical efficacy rate in 34 patients aged 15-79 with infectious destructive lung lesions.
    • The antibiotic was effective against 85% of 39 tested aerobic and anaerobic bacterial strains, with a bacteriological efficacy of 71.4%.
    • Adverse reactions were reported in 11.7% of patients, indicating a generally favorable tolerance profile.

    Impact:

    • The findings support the recommendation of cefpiramide for treating severe and complicated infectious destructive lung diseases.
    • This study contributes to the evidence base for cefpiramide's utility in managing serious pulmonary infections.

    More Related Videos

    P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

    P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

    Published on: June 15, 2020

    Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

    Assay Development for High-Throughput Drug Screening Against Mycobacteria

    Published on: October 25, 2024

    Related Concept Videos

    Drugs Used in Lower Respiratory Disorders: Overview01:17

    Drugs Used in Lower Respiratory Disorders: Overview

    Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
    Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
    Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

    Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

    Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
    Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
    Pulmonary Tuberculosis V01:28

    Pulmonary Tuberculosis V

    Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
    Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
    Respiratory Syncytial Virus Disease01:29

    Respiratory Syncytial Virus Disease

    Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
    Cryptococcal Meningitis01:27

    Cryptococcal Meningitis

    Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
    Chronic Obstructive Pulmonary Disease II: Emphysema01:23

    Chronic Obstructive Pulmonary Disease II: Emphysema

    Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.